An impurity was found in Pfizer’s heart and blood pressure medication Accupril that has led to a recall of several lots of the drug. The contaminant, known as a nitrosamine, can be carcinogenic at high levels and can increase a patient’s risk of developing cancer over time.
Patients are advised against stopping their medication at this time. Rather, those that are concerned that they may have pills from ...
continue reading...
Drug manufacturer Pfizer has moved to recall several lots of blood pressure pills over concerns that the medication may have been tainted with a carcinogenic contaminant. The affected medications include Accuretic, which is a tablet distributed by Pfizer itself, as well as a line of medications distributed by a second manufacturer known as Greenstone. The Greenstone lots include a pill that combines quinapril hydrochloride and hydrochlorothiazide ...
Patients taking drugs manufactured by Pfizer, Eli Lilly & Co., and AbbVie for arthritis may find new warnings attached to those medications. The FDA is seeking additional language warning of serious side effects and possible fatalities associated with the drugs.
The medications are part of a class of arthritis drugs known as JAK inhibitors. They work by blocking enzymes in the body known to cause arthritic inflammation ...
continue reading...Patients taking Chantix to help them quit smoking may find the drug a bit harder to locate as multiple lots have been recalled for possible contamination with, of all things, a probable human carcinogen.
Nine lots of varenicline (the drug name for Chantix) have been recalled by Pfizer. Most of the affected lots were still in warehouses and awaiting distribution, however, the company has halted further releases of the medication into ...
continue reading...Citing data gathered from an ongoing clinical trial, the United States Food and Drug Administration has issued a black box warning for Pfizer’s rheumatoid arthritis and ulcerative colitis medication Xeljanz. The warning, the agency’s most severe, also applies to the extended release version of the drug, Xeljanz XR.
The warnings stem from the discovery of an increased risk of blood clots and the death of ...
continue reading...Pharmaceutical company Pfizer Inc. is reviewing a suggestion from the U.S. Food and Drug Administration (FDA) to modify safety warnings on labels of the popular antidepressant Zoloft. According to Bloomberg, court papers filed earlier this month reveal that the FDA asked Pfizer in August to update Zoloft’s warnings to reflect findings by some researchers that the drug may increase the risk of congenital heart defects in ...
